September 29, 2026
Top Real-World Evidence Companies for Pharma & Biotech
"Neurodiscovery AI has been instrumental in transforming real-world neurology data into actionable insights that improve patient care and sustain private practice. Their commitment to neurologists—ensuring both business success and innovation in drug discovery—makes them an invaluable partner to NeuroNet and the entire field of community neurology."
Joseph V. Fritz PhDPartner,
Real-world evidence companies range from broad, multi-therapeutic-area data platforms to specialists built around a single disease category. Choosing among them depends less on brand recognition than on what a specific study or submission actually needs: claims breadth, clinical depth, regulatory-grade methodology, or therapeutic-area specificity. This roundup groups the RWE companies pharma and biotech sponsors most commonly evaluated by operational archetype, broad aggregators, oncology specialists, indication-specific specialists, federated networks, and EHR-based regulatory-grade platforms, so the comparison reflects how these companies actually differ, not just brand recognition.
What to Look for in an RWE Company
Before comparing specific vendors, it helps to know what actually differentiates them. Most RWE solutions fall along a few consistent lines:
-
Breadth vs. clinical depth. Claims-based platforms tend to cover huge patient populations but capture little clinical nuance. Clinical data platforms go the other direction, narrower coverage in exchange for detail that claims codes can't capture.
-
Regulatory-grade methodology. Not every RWE vendor is built for submission-grade evidence. Some are built for commercial analytics, and the two use cases call for different levels of methodological rigor and auditability.
-
Therapeutic-area specificity. General-purpose platforms often lack the clinical granularity that complex or heterogeneous conditions require, which is where disease-specific RWE providers tend to outperform broader platforms.
-
Data linkage and interoperability. Some companies specialize in connecting other companies' data sources together rather than owning a dataset themselves.
Category 1: Broad Longitudinal Aggregators
Optum Life Sciences
Optum Life Sciences draws on one of the largest longitudinal clinical and claims datasets in the industry, spanning commercial, HEOR, R&D, and epidemiology use cases. Frost & Sullivan named Optum Life Sciences a 2025 Leader in Real-World Evidence Solutions, and it's frequently evaluated by sponsors needing broad, cross-therapeutic data depth alongside HEOR expertise.
IQVIA
IQVIA is one of the largest and most established real-world evidence companies globally, offering RWE services across nearly every therapeutic area, along with clinical research, commercial analytics, and technology services. Its scale makes it a common default for sponsors that need broad, cross-indication coverage, though that same breadth can mean less clinical depth in any single disease area compared to a specialist.
Komodo Health
Komodo Health built its business around an all-payer claims dataset it calls the Healthcare Map, used primarily for patient-journey analytics, treatment pattern research, and rare-disease epidemiology. Its all-payer design makes it a common choice when a study needs to identify small, dispersed patient populations across the broader healthcare system.
Datavant
Datavant functions less like a traditional data owner and more like connective infrastructure, linking data across separate real-world data sources through tokenization. Its 2025 acquisition of Aetion, a regulatory-grade causal-analytics platform, combined data linkage with methodology built specifically for FDA-facing real-world evidence.
Category 2: Oncology Specialists
Flatiron Health
Flatiron Health, now part of Roche, is one of the most established real-world evidence vendors specifically in oncology, built on curated EHR data from community and academic cancer centers. It's frequently used for oncology-specific external control arms and clinical outcomes research.
ConcertAI
ConcertAI combines real-world oncology data with applied AI and clinical expertise, positioning itself as an evidence-generation partner rather than a pure data vendor. It's commonly evaluated alongside Flatiron for oncology-specific RWE work.
Tempus
Tempus differentiates through genomic and molecular data layered onto its clinical real-world dataset, making it a frequent choice for oncology studies where molecular profiling is central to the research question.
Category 3: Indication-Specific Specialists
Where oncology has several dedicated specialists, most other therapeutic areas are still served primarily by broad, general-purpose platforms. Neurology is a clear exception.
NeuroDiscovery AI
NeuroDiscovery AI is built specifically for neurology, covering 6M+ patient records and 3M+ active patients, across 1,000+ providers and 100+ clinical sites in 16+ U.S. states. Rather than treating neurology as one indication among many, the platform is built to extract the kind of clinical detail, functional scores, symptom severity, imaging findings, that general-purpose RWE companies often can't reliably pull from unstructured neurology documentation. Most sponsors pair a broad platform for cross-indication work with a specialist like this where a disease's clinical complexity demands it.
Category 4: Federated Networks and Health-System Data
TriNetX
TriNetX, majority-owned by The Carlyle Group since 2020, operates a federated global network that lets researchers query de-identified EHR, claims, and mortality data across participating healthcare organizations without the data ever leaving each institution. Its self-service query interface makes it a common choice for early feasibility work across many therapeutic areas, including neurology.
Truveta
Truveta is built on a consortium model, drawing data directly from participating U.S. health systems, which gives it clinical depth closer to source EHR data than most claims-based platforms can offer.
Category 5: EHR-Based and Regulatory-Grade Platforms
Veradigm
Veradigm provides EHR-derived real-world data intended to support regulatory-grade research, and is frequently cited alongside IQVIA and Flatiron as a source considered suitable for FDA-facing evidence generation.
How These RWE Companies Compare
| Company | Category | Data Source | Delivery Model | Best For |
|---|---|---|---|---|
| NeuroDiscovery AI | Indication-specific specialist | EHR, clinical notes | Direct license | Neurology trial design and evidence generation |
| Optum Life Sciences | Broad aggregator | Claims, EHR | Direct license | Cross-therapeutic depth with HEOR support |
| IQVIA | Broad aggregator | Claims, EHR, registries | Direct license | Enterprise-scale, multi-indication studies |
| Komodo Health | Broad aggregator | All-payer claims | Direct license | Rare-disease epidemiology, treatment patterns |
| Datavant (incl. Aetion) | Data linkage infrastructure | Cross-source (linked) | Tokenized linkage | FDA-facing evidence requiring data connectivity |
| Flatiron Health | Oncology specialist | Curated EHR | Direct license | Oncology external control arms |
| ConcertAI | Oncology specialist | EHR, clinical data | Direct license | Oncology evidence generation partnerships |
| Tempus | Oncology specialist | EHR, genomics | Direct license | Oncology studies needing molecular profiling |
| TriNetX | Federated network | EHR, claims, mortality | Federated query | Cross-institution feasibility and cohort building |
| Truveta | Federated network | Health-system EHR | Consortium access | Clinical-depth studies close to source EHR |
| Veradigm | EHR-based, regulatory-grade | EHR | Direct license | FDA-facing evidence generation |
Conclusion
There's no single best real-world evidence company, only the right fit for a specific research question. Broad platforms like Optum, IQVIA, Komodo Health, and Datavant offer scale and cross-indication reach. Oncology specialists like Flatiron, ConcertAI, and Tempus offer clinical and molecular depth in one disease area. Federated networks like TriNetX and Truveta offer access across institutions. For neurology specifically, where much of the clinically meaningful detail sits in unstructured documentation that general-purpose platforms often can't reliably extract, a therapeutic-area specialist like NeuroDiscovery AI tends to close a gap the broader platforms leave open.
To see how NeuroDiscovery AI's neurology-specific real-world data and evidence generation capabilities work, explore.
Frequently Asked Questions
- What is a real-world evidence company?
- A real-world evidence company provides data, analytics, or methodology that turns real-world data, such as EHRs, claims, or registries, into clinical evidence used for regulatory submissions, HEOR, or commercial strategy.
- How do RWE companies differ from CROs?
- CROs typically run and manage clinical trials on a sponsor's behalf. RWE companies provide the real-world data and analytical methods used to generate evidence outside a trial setting, though the two increasingly overlap on services like external control arms.
- What should I look for in an RWE vendor?
- Key factors include whether the data and methodology are regulatory-grade, whether the vendor has depth in your specific therapeutic area, how the data is sourced and linked, and whether the underlying methodology is transparent and auditable.
- Are there real-world evidence companies specific to neurology?
- Most major RWE companies serve many therapeutic areas at once. NeuroDiscovery AI is built specifically for neurology, focused on extracting clinical detail from unstructured neurology documentation that general-purpose platforms often miss.
- How is real-world evidence data used by pharma companies?
- Pharma companies use RWE for external control arms, post-approval safety monitoring, health economics and outcomes research, label expansion support, and increasingly for informing clinical trial design before a protocol is finalized.
